61 results on '"Del Mastro, A."'
Search Results
2. Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
3. Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
4. Role of dose-dense chemotherapy in high-risk early breast cancer
5. Fertility, sexuality and cancer in young adult women
6. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study
7. Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al.
8. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology
9. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
10. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies
11. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis
12. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence
13. Pharmacokinetics of Trastuzumab in Haemodialysis
14. Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases
15. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
16. 151Evidence of impaired left ventricular strain and torsion despite normal ejection fraction in cardiac transplanted children and adolescents: a speckle-tracking study
17. Gonadotropin-Releasing Hormone Analogue for Premenopausal Women With Breast Cancer—Reply
18. Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial
19. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors
20. Letrozole withdrawal response in locally advanced breast cancer
21. Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer: A Randomized Trial
22. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study
23. Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
24. Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer
25. The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients
26. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group
27. Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
28. A short course of pegylated interferon-α in acute HCV hepatitis
29. Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study
30. Fertility Preservation Strategies for Breast Cancer Patients
31. Taxane-containing chemotherapy in the treatment of early breast cancer patients
32. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
33. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
34. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
35. Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
36. Reply to “Weekly paclitaxel in elderly breast cancer patients”, by C. Smorenburg et al. (Ann Oncol 2005; 16: 1979)
37. Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients
38. Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)
39. A multistep randomized phase II/III trial comparing oxaliplatin (OXA)+5 fluorouracil (FU) to vinorelbine (VIN)+FU (FUN) after taxane (T)/anthracycline (A) failure in advanced/metastatic breast cancer (MBC) patients (pts): Final results.: 660
40. Mouse ADAM33: Two Splice Variants Differ in Protein Maturation and Localization
41. Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer: A Dose-Finding Study
42. PREVENTION OF CHEMOTHERAPY INDUCED EARLY MENOPAUSE BY TEMPORARY OVARIAN SUPPRESSION WITH GOSERELIN IN PREMENOPAUSAL BREAST CANCER PATIENTS. A PHASE II STUDY
43. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients
44. Weekly paclitaxel - phase II trial in older patients with advanced breast cancer: A GIOGer study
45. A MULTISTEP RANDOMIZED PHASE II/III TRIAL COMPARING OXALIPLATIN (OXA)+ 5 FLUOROURACIL (FU) TO VINORELBINE (VIN)+FU (FUN) AFTER TAXANE (T)/ANTHRACYCLINE (A) FAILURE IN ADVANCED/METASTATIC BREAST CANCER (MBC) PATIENTS (PTS): 245
46. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness
47. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study
48. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer
49. Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer
50. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.